Who are Augmenting: Antidepressant + Bupropion-SR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BuproprionSR, Active bupropion, No counseling, Bupropion XL 300, generic bupropion, Welbutrin XL, Active bupropion-Placebo gum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/augmenting-antidepressant-bupropion-sr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Augmenting: Antidepressant + Bupropion-SR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Augmenting: Antidepressant + Bupropion-SR (Augmenting: Antidepressant + Bupropion-SR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor (NDRI); antidepressant augmentation strategy. Area: Psychiatry / Mental Health.

phase 3 Norepinephrine-dopamine reuptake inhibitor (NDRI); antidepressant augmentation strategy Norepinephrine transporter (NET); dopamine transporter (DAT) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Augmenting: Antidepressant + Bupropion-SR (Augmenting: Antidepressant + Bupropion-SR) — VA Office of Research and Development. Bupropion-SR augments antidepressant therapy by inhibiting norepinephrine and dopamine reuptake, addressing residual depressive symptoms in patients with incomplete response to initial antidepressant monotherapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Augmenting: Antidepressant + Bupropion-SR TARGET	Augmenting: Antidepressant + Bupropion-SR	VA Office of Research and Development	phase 3	Norepinephrine-dopamine reuptake inhibitor (NDRI); antidepressant augmentation strategy	Norepinephrine transporter (NET); dopamine transporter (DAT)
BuproprionSR	BuproprionSR	National Institute of Mental Health (NIMH)	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Active bupropion, No counseling	Active bupropion, No counseling	University of Wisconsin, Madison	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Bupropion XL 300	Bupropion XL 300	Washington University School of Medicine	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET), Dopamine transporter (DAT)
generic bupropion	generic bupropion	University of Michigan	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET); Dopamine transporter (DAT)
Welbutrin XL	Welbutrin XL	Massachusetts General Hospital	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Active bupropion-Placebo gum	Active bupropion-Placebo gum	University of Wisconsin, Madison	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor (NDRI); antidepressant augmentation strategy class)

VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Augmenting: Antidepressant + Bupropion-SR — Competitive Intelligence Brief. https://druglandscape.com/ci/augmenting-antidepressant-bupropion-sr. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab